摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-乙氧基羰基环己-3-烯-4-硼酸频哪醇酯 | 1049004-32-1

中文名称
1-乙氧基羰基环己-3-烯-4-硼酸频哪醇酯
中文别名
4-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-3-环己烯e-1-羧酸乙酯
英文名称
(RS)-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-cyclohex-3-enecarboxylic acid ethyl ester
英文别名
ethyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-ene-1-carboxylate;ethyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-enecarboxylate;1-ethoxycarbonylcyclohex-3-en-4-boronic acid pinacol ester
1-乙氧基羰基环己-3-烯-4-硼酸频哪醇酯化学式
CAS
1049004-32-1
化学式
C15H25BO4
mdl
——
分子量
280.172
InChiKey
ZREZDODZGZVRBD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    312.6±52.0 °C(Predicted)
  • 密度:
    1.03

计算性质

  • 辛醇/水分配系数(LogP):
    2.91
  • 重原子数:
    20
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.8
  • 拓扑面积:
    44.8
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335

SDS

SDS:6ee0c2fb54cc7203e6976f0de132703b
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-(Ethoxycarbonyl)cyclohexene-1-boronic acid, pinacol ester
Synonyms: 4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)cyclohex-3-ene-1-carboxylic acid ethyl ester

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-(Ethoxycarbonyl)cyclohexene-1-boronic acid, pinacol ester
CAS number: 1049004-32-1

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C15H25BO4
Molecular weight: 280.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    1-乙氧基羰基环己-3-烯-4-硼酸频哪醇酯二氟化氢钾 作用下, 以 丙酮 为溶剂, 反应 4.0h, 以100%的产率得到potassium (RS)-(4-(ethoxycarbonyl)cyclohex-1-enyl)trifluoroborate
    参考文献:
    名称:
    Cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists
    摘要:
    本发明提供了4H,6H-5-氧杂-2,3,10b-三氮杂-苯并[e]吖啶,其作为V1a受体调节剂,特别是作为V1a受体拮抗剂,其制备方法,含有它们的药物组合物以及它们作为药物的用途。本发明的活性化合物在治疗作用上在经前痛、男性或女性性功能障碍、高血压、慢性心力衰竭、抗利尿素的不当分泌、肝硬化、肾病综合征、焦虑、抑郁症、强迫性障碍、自闭症谱系障碍、精神分裂症和攻击性行为等疾病中有用。
    公开号:
    US20140221350A1
  • 作为产物:
    参考文献:
    名称:
    [EN] MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE
    [FR] MODULATEURS D'INDOLÉAMINE 2,3-DIOXYGÉNASE
    摘要:
    提供了化学式(I)的IDO1抑制剂化合物及其药用盐,它们的药物组合物,它们的制备方法,以及它们在预防和/或治疗疾病中的使用方法。
    公开号:
    WO2019111107A1
点击查看最新优质反应信息

文献信息

  • [EN] MERTK DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION DE MERTK ET LEURS UTILISATIONS
    申请人:KYMERA THERAPEUTICS INC
    公开号:WO2020010210A1
    公开(公告)日:2020-01-09
    The present invention provides compounds, compositions thereof, and methods of using the same.
    本发明提供了化合物、其组合物以及使用相同的方法。
  • [EN] 2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS<br/>[FR] DÉRIVÉS DE 2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE ET COMPOSÉS CORRESPONDANTS UTILISÉS EN TANQUE QUE AGONISTES DU RÉCEPTEUR D'HYDROCARBURE ARYLE (AHR) UTILISÉS POUR LE TRAITEMENT DE, P.EX., DE L'ANGIOGENÈSE IMPLIQUÉE OU DE TROUBLES INFLAMMATOIRES
    申请人:IKENA ONCOLOGY INC
    公开号:WO2021127302A1
    公开(公告)日:2021-06-24
    2-(1H-lndole-3-carbonyl)-thiazole-4-carboxamide derivatives and the corresponding imidazole, oxazole and thiophene derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 27 to 32 and 59 to 219; examples 1 to 8; compounds 1-1 to 1-97; tables 1-a, 2 and 3).
    2-(1H-吲哚-3-甲酰基)-噻唑-4-羧酰胺衍生物及相应的咪唑、噁唑和噻吩衍生物以及相关化合物作为芳香烃受体(AHR)激动剂,用于治疗涉及血管生成的疾病,例如视网膜病变、银屑病、类风湿性关节炎、肥胖和癌症,或炎症性疾病。本说明书揭示了示例化合物的合成和表征以及其药理数据(例如第27至32页和59至219页;示例1至8;化合物1-1至1-97;表1-a、2和3)。
  • PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS
    申请人:Forma Therapeutics, Inc.
    公开号:US20160185785A1
    公开(公告)日:2016-06-30
    The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X 1 , X 2 , R 1 -R 5 , R 5′ and R 6 are described herein.
    这项发明涉及USP7抑制剂,用于治疗癌症、神经退行性疾病、免疫紊乱、炎症性疾病、心血管疾病、缺血性疾病、病毒感染和疾病、细菌感染和疾病,具有以下结构式: 其中m、n、X1、X2、R1-R5、R5'和R6如本文所述。
  • 縮合二環式ヘテロ環誘導体
    申请人:第一三共株式会社
    公开号:JP2016141632A
    公开(公告)日:2016-08-08
    【課題】優れたレチノイン酸受容体関連オーファン受容体γt阻害作用を有し、乾癬等の治療薬として有用な化合物の提供。【解決手段】一般式(I)で表される化合物又はその薬理上許容される塩。[環Aはピロール環、イミダゾール環又はピラゾール環;環Bは置換/非置換のベンゼン環、シクロヘキサジエン環、シクロペンテン環、シクロヘキセン環等;R1はH、ハロゲン原子等;R2はH、ハロゲン原子、C1−C6アルキル基等;式=Q−T−で表される基は式=CH−CH=CH−で表される基等;Zは式=CH−で表される基等;式−U−V(CO2H)−W−で表される基は、式−CH=CH−C(CO2H)=CH−で表される基等]【選択図】なし
    提供具有优良的视黄醇酸受体相关孤儿受体γt抑制作用,并且作为银屑病等治疗药物有用的化合物。通式(I)表示的化合物或其药理上可接受的盐。【环A为吡咯环、咪唑环或吡唑环;环B为取代/非取代的苯环、环己二烯环、环戊二烯环、环己烯环等;R₁为H、卤原子等;R₂为H、卤原子、C₁−C₆烷基等;基=Q−T−表示的基为基=CH−CH=CH−等;Z为基=CH−等;基表示为式−U−V(CO₂H)−W−的基为,基表示为式−CH=CH−C(CO₂H)=CH−等】【选择图】无
  • C-17 BICYCLIC AMINES OF TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY
    申请人:BRISTOL-MYERS SQUIBB COMPANY
    公开号:US20130296554A1
    公开(公告)日:2013-11-07
    Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 bicyclic amines of triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.
    具有药物和生物活性的化合物、其药物组合物及其使用方法在此予以说明。特别是,提供了具有独特抗病毒活性的C-17双环胺三萜类化合物,作为HIV成熟抑制剂,由公式I、II和III所示的化合物代表:这些化合物可用于治疗HIV和艾滋病。
查看更多